secwatch.observer — SEC 8-K summary
======================================

Issuer:     Esperion Therapeutics, Inc. (ESPR)
CIK:        0001434868
Form:       8-K
Filed at:   2025-08-05T23:59:59+00:00
Accession:  0001628280-25-037601
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Esperion Q2 revenue $82.4M (+12% Y/Y); first operating income of $15M; expects sustainable profitability Q1 2026
--------------------------------------------------------------------------------

- U.S. net product revenue $40.3M, +42% Y/Y; total prescriptions up 10% sequential.
- Net loss per share $0.02 vs $0.33 loss a year ago; operating income from ongoing business $15M.
- Reached settlements with three ANDA filers to block generic NEXLETOL until 2040.
- Royalty revenue from European partner up 30% sequentially to $13.6M; Japan approval on track for H2 2025.
- Reiterated FY2025 opex $215-235M; cash $86.1M; shares outstanding ~200.2M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1434868/000162828025037601/0001628280-25-037601-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1434868/000162828025037601/espr-20250805.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-037601

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer